Cargando…
A splenic-targeted versatile antigen courier: iPSC wrapped in coalescent erythrocyte-liposome as tumor nanovaccine
The major obstacles for tumor vaccine to be surmounted are the lack of versatile property and immunity-inducing effectiveness. Induced pluripotent stem cells (iPSCs) expressed various antigens the same as multiple types of tumors, providing a promising source of wide-spectrum cancer vaccines. The da...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Association for the Advancement of Science
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8386930/ https://www.ncbi.nlm.nih.gov/pubmed/34433569 http://dx.doi.org/10.1126/sciadv.abi6326 |
_version_ | 1783742349302562816 |
---|---|
author | Zhai, Yuewen He, Xiaorong Li, Ying Han, Ran Ma, Yuying Gao, Peng Qian, Zhiyu Gu, Yueqing Li, Siwen |
author_facet | Zhai, Yuewen He, Xiaorong Li, Ying Han, Ran Ma, Yuying Gao, Peng Qian, Zhiyu Gu, Yueqing Li, Siwen |
author_sort | Zhai, Yuewen |
collection | PubMed |
description | The major obstacles for tumor vaccine to be surmounted are the lack of versatile property and immunity-inducing effectiveness. Induced pluripotent stem cells (iPSCs) expressed various antigens the same as multiple types of tumors, providing a promising source of wide-spectrum cancer vaccines. The damaged erythrocyte membrane entrapped by spleen could be developed as antigen deliverer for enhancing acquired immunity. Here, the modified lipid materials were used to dilate erythrocyte membrane to fabricate coalescent nanovector, which not only preserved the biological characteristics of erythrocyte membrane but also remedied the defect of insufficient drug loading capacity. After wrapping iPSC protein, the nanovaccine iPSC@RBC-Mlipo exhibited obvious splenic accumulation, systemic specific antitumor immunity evocation, and effective tumor expansion and metastasis inhibition in mice. Hence, our research may provide a prospective strategy of efficient tumor vaccine for clinical practice. |
format | Online Article Text |
id | pubmed-8386930 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | American Association for the Advancement of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-83869302021-08-31 A splenic-targeted versatile antigen courier: iPSC wrapped in coalescent erythrocyte-liposome as tumor nanovaccine Zhai, Yuewen He, Xiaorong Li, Ying Han, Ran Ma, Yuying Gao, Peng Qian, Zhiyu Gu, Yueqing Li, Siwen Sci Adv Research Articles The major obstacles for tumor vaccine to be surmounted are the lack of versatile property and immunity-inducing effectiveness. Induced pluripotent stem cells (iPSCs) expressed various antigens the same as multiple types of tumors, providing a promising source of wide-spectrum cancer vaccines. The damaged erythrocyte membrane entrapped by spleen could be developed as antigen deliverer for enhancing acquired immunity. Here, the modified lipid materials were used to dilate erythrocyte membrane to fabricate coalescent nanovector, which not only preserved the biological characteristics of erythrocyte membrane but also remedied the defect of insufficient drug loading capacity. After wrapping iPSC protein, the nanovaccine iPSC@RBC-Mlipo exhibited obvious splenic accumulation, systemic specific antitumor immunity evocation, and effective tumor expansion and metastasis inhibition in mice. Hence, our research may provide a prospective strategy of efficient tumor vaccine for clinical practice. American Association for the Advancement of Science 2021-08-25 /pmc/articles/PMC8386930/ /pubmed/34433569 http://dx.doi.org/10.1126/sciadv.abi6326 Text en Copyright © 2021 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works. Distributed under a Creative Commons Attribution NonCommercial License 4.0 (CC BY-NC). https://creativecommons.org/licenses/by-nc/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial license (https://creativecommons.org/licenses/by-nc/4.0/) , which permits use, distribution, and reproduction in any medium, so long as the resultant use is not for commercial advantage and provided the original work is properly cited. |
spellingShingle | Research Articles Zhai, Yuewen He, Xiaorong Li, Ying Han, Ran Ma, Yuying Gao, Peng Qian, Zhiyu Gu, Yueqing Li, Siwen A splenic-targeted versatile antigen courier: iPSC wrapped in coalescent erythrocyte-liposome as tumor nanovaccine |
title | A splenic-targeted versatile antigen courier: iPSC wrapped in coalescent erythrocyte-liposome as tumor nanovaccine |
title_full | A splenic-targeted versatile antigen courier: iPSC wrapped in coalescent erythrocyte-liposome as tumor nanovaccine |
title_fullStr | A splenic-targeted versatile antigen courier: iPSC wrapped in coalescent erythrocyte-liposome as tumor nanovaccine |
title_full_unstemmed | A splenic-targeted versatile antigen courier: iPSC wrapped in coalescent erythrocyte-liposome as tumor nanovaccine |
title_short | A splenic-targeted versatile antigen courier: iPSC wrapped in coalescent erythrocyte-liposome as tumor nanovaccine |
title_sort | splenic-targeted versatile antigen courier: ipsc wrapped in coalescent erythrocyte-liposome as tumor nanovaccine |
topic | Research Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8386930/ https://www.ncbi.nlm.nih.gov/pubmed/34433569 http://dx.doi.org/10.1126/sciadv.abi6326 |
work_keys_str_mv | AT zhaiyuewen asplenictargetedversatileantigencourieripscwrappedincoalescenterythrocyteliposomeastumornanovaccine AT hexiaorong asplenictargetedversatileantigencourieripscwrappedincoalescenterythrocyteliposomeastumornanovaccine AT liying asplenictargetedversatileantigencourieripscwrappedincoalescenterythrocyteliposomeastumornanovaccine AT hanran asplenictargetedversatileantigencourieripscwrappedincoalescenterythrocyteliposomeastumornanovaccine AT mayuying asplenictargetedversatileantigencourieripscwrappedincoalescenterythrocyteliposomeastumornanovaccine AT gaopeng asplenictargetedversatileantigencourieripscwrappedincoalescenterythrocyteliposomeastumornanovaccine AT qianzhiyu asplenictargetedversatileantigencourieripscwrappedincoalescenterythrocyteliposomeastumornanovaccine AT guyueqing asplenictargetedversatileantigencourieripscwrappedincoalescenterythrocyteliposomeastumornanovaccine AT lisiwen asplenictargetedversatileantigencourieripscwrappedincoalescenterythrocyteliposomeastumornanovaccine AT zhaiyuewen splenictargetedversatileantigencourieripscwrappedincoalescenterythrocyteliposomeastumornanovaccine AT hexiaorong splenictargetedversatileantigencourieripscwrappedincoalescenterythrocyteliposomeastumornanovaccine AT liying splenictargetedversatileantigencourieripscwrappedincoalescenterythrocyteliposomeastumornanovaccine AT hanran splenictargetedversatileantigencourieripscwrappedincoalescenterythrocyteliposomeastumornanovaccine AT mayuying splenictargetedversatileantigencourieripscwrappedincoalescenterythrocyteliposomeastumornanovaccine AT gaopeng splenictargetedversatileantigencourieripscwrappedincoalescenterythrocyteliposomeastumornanovaccine AT qianzhiyu splenictargetedversatileantigencourieripscwrappedincoalescenterythrocyteliposomeastumornanovaccine AT guyueqing splenictargetedversatileantigencourieripscwrappedincoalescenterythrocyteliposomeastumornanovaccine AT lisiwen splenictargetedversatileantigencourieripscwrappedincoalescenterythrocyteliposomeastumornanovaccine |